Metronidazole vaginal gel 0.75% is a prescription preparation intended for intravaginal use in appropriate cases of bacterial vaginosis (BV). The concentration means 7.5 mg of metronidazole per gram of gel; it is not a tablet strength, a recommendation to use a particular amount or evidence that every 0.75% product is the same. The vaginal metronidazole overview places this product in context alongside the separate 1.3% single-dose formulation.
The distinguishing feature of the 0.75% product is its route-specific formulation and associated applicator instructions. The tube and applicators may appear in a branded or generic pharmacy listing. Although some dermatologic metronidazole gels also say 0.75%, those are intended for skin use and have different product labeling. A vaginal versus topical gel comparison explains why concentration alone is not enough to establish equivalence.
This page focuses on the actual U.S. 0.75% vaginal product: label identity, packaging, concentration, route restrictions and what to confirm before a prescription is filled. It does not prescribe a course or make claims about specific pharmacies having stock. For access logistics rather than product science, use the vaginal gel pharmacy purchasing guide.
In a metronidazole 0.75% vaginal gel, the concentration is 7.5 mg of active ingredient per gram of gel. This is distinct from oral tablet strengths expressed in milligrams per tablet, and it should not be mistaken for a skin-gel indication. Product labels also specify vaginal administration and provide instructions suited to the supplied applicator system.
The container size and number of applicators are separate identifiers from the concentration. A single tube might contain more material than is administered at one time; the prescription and product-specific instructions determine how the supplied package is used. Avoid converting concentration into a patient-directed dose based on an online calculator.
| Product feature | 0.75% vaginal gel | Do not confuse with |
|---|---|---|
| Active ingredient | Metronidazole 7.5 mg/g | 250 mg or 500 mg oral tablets |
| Route | Intravaginal | 0.75% rosacea skin gel |
| Presentation | Tube or other approved package with vaginal applicators | 1.3% single prefilled applicator |
| Label purpose | Treatment of BV when prescribed | Trichomoniasis treatment |
| Dispensing check | Correct package, concentration and directions | Appearance of generic website listing |
FDA-approved 0.75% vaginal gel labeling describes product-specific directions and patient precautions, including use of vaginal applicators. The CDC lists 0.75% intravaginal gel among recommended treatment options for symptomatic BV, but general guideline information is not a substitute for an individual prescription. Clinical decisions can depend on patient circumstances and the clinician's assessment.
Do not apply instructions for Nuvessa 1.3% to a 0.75% tube. The formulation and labeled administration scheme are distinct. If the pharmacy labels conflict with instructions given by the clinician, request clarification before using the medicine.
Approved 0.75% vaginal products share the relevant active ingredient, concentration and route, but inactive ingredients, packaging details and labeler names may vary within allowed limits. These can be important when a patient has a documented sensitivity to an excipient. FDA approval is more informative than a seller's claim that two gels look or feel alike.
Check the currently dispensed label and patient leaflet for the exact ingredients and precautions. Ask the pharmacist to verify any concern involving prior reactions, vaginal irritation, other medicines or medical history rather than assuming that a familiar trade name makes the formulation universally suitable.
Vandazole is a branded 0.75% vaginal metronidazole gel; approved generic 0.75% products occupy the same basic route and concentration category. Approval and any pharmacy substitution must still be checked against the precise product and applicable regulations. A branded listing on an information database does not prove that a shelf has the item today.
The dedicated generic vaginal gel guide covers equivalence, package identification and the difference between a generic approval and a retailer inventory promise. This page remains focused on what makes the 0.75% product identifiable.
Nuvessa 1.3% uses a single prefilled applicator and has its own FDA labeling. The 0.75% formulation is described separately and is not automatically interchangeable with the single-dose 1.3% presentation. The percentages are not simply two concentrations that the patient can adjust by changing the amount of gel used.
FDA has approved a generic 1.3% vaginal gel referencing Nuvessa, which is an equivalence relationship within that strength and route; it does not create an equivalence between 0.75% and 1.3%. See Nuvessa versus Vandazole for the product comparison.
On the pharmacy label, look for vaginal use, the 0.75% concentration, the exact prescribed directions, quantity and the patient's name. Check the supplied applicators and any patient leaflet. If a web catalog shows a carton that differs from what you received, the pharmacist can explain whether that reflects a permissible label or package variation.
Do not rely on a product image to identify the medicine or assume the number of applicators from an old web listing. The final dispensed labeling is the basis for clarification with the pharmacist.
The product's price depends on the exact package, brand or generic identity, the dispensing pharmacy and insurance arrangements. A 0.75% vaginal gel quote cannot establish what a 1.3% product will cost. No evergreen article can reliably display real-time inventory, coupon eligibility or insurer payment for an individual patient.
Use vaginal gel price factors to prepare questions for your pharmacy, or vaginal product availability checks to learn how to verify listings.
Package labels may express the net contents of a tube in grams, while the prescription specifies individual applications and a course. The amount in a tube does not, by itself, state the correct number of applications or instructions. Similar-looking cartons may include different numbers of applicators, and those details should be checked against the exact label.
This distinction is especially useful when comparing retail catalog descriptions. A large carton photograph may make two products appear equivalent even when only one includes the applicators or directions that match the order. Ask the pharmacist to clarify all discrepancies instead of trying to divide the tube's contents into self-calculated doses.
Although vaginal administration differs from oral systemic therapy, metronidazole vaginal gel still has its own contraindications, cautions and potential adverse effects. Information about previous reactions to metronidazole, current medicines, pregnancy or breastfeeding can affect the clinician's assessment. The exact product insert should be reviewed rather than transferring warnings verbatim from a tablet or skin cream page.
Vaginal discomfort or possible yeast symptoms during or after therapy are examples of concerns worth discussing with a professional. An online guide cannot determine the cause of a new symptom. Seek medical assessment when symptoms are severe, unusual or worsening.
If symptoms have not resolved or return, repeat treatment is not automatically the next appropriate action. A clinician may need to reconsider the diagnosis, review adherence, evaluate other causes of discharge or irritation and discuss the nature of any recurrence. Changing the vaginal gel concentration without direction is not an appropriate way to manage persistent symptoms.
Our recurrent BV overview examines that separate clinical problem. The 0.75% formulation guide is intended to support identification of the product that was prescribed, not to give a repeated-treatment schedule.
Confirm that the prescription is for intravaginal metronidazole, not oral or skin treatment. Then verify 0.75% concentration, approved product and package, the applicators provided and the exact directions printed on the dispensed label. These checks guard against the common mistake of matching only the ingredient or percentage.
When any feature is inconsistent, ask the prescribing clinician or pharmacist before using the product. The purpose of comparing labels is to support correct prescription dispensing, never to self-prescribe a different formulation.
It means a vaginal gel containing metronidazole at 7.5 mg per gram. It identifies the concentration, not a patient-specific dose.
No. Products intended for the vagina and skin have different labeling, formulations and approved uses.
Yes. Vandazole is a branded intravaginal metronidazole gel at 0.75%; availability must be checked with a pharmacy.
Not necessarily. Approved products may differ in permitted inactive ingredients and packaging details. Check the exact label.
Not on your own. They are distinct formulations with different labeled presentations and should not be substituted without appropriate professional review.
Vaginal gel products are supplied with applicators according to the specific labeled package. Confirm the number and style at dispensing.
No. Metronidazole vaginal gel 0.75% requires a valid U.S. prescription.
CDC does not recommend vaginal metronidazole gel for trichomoniasis because it is less effective than appropriate systemic therapy.
Approved generic substitution depends on the exact product, the prescription and applicable law. A pharmacist can verify the appropriate equivalence.
No. An FDA or DailyMed drug label does not provide real-time retail inventory information.